Table 1.
Comparisons between means ± SD of GFR, RPF, urine volume, urine sodium excretion rate, etc. taken on weeks 11–12 (Group GXA) vs. weeks 13–14 (Group GXB) or among different G1–G6 groups. In each group, worsening of clinical parameters underlined, improvements in bold print (weeks 13–14, Group GXB, vs. weeks 11–12, Group GXA).
Fig 1.
Progressive weight gain of untreated cirrhotic rats (G3, red line) and of cirrhotic rats treated with diuretics (G4, yellow line) or with diuretics plus clonidine (G5, blue line).
Further groups depicted: G1 (healthy controls, black line), G6 (cirrhotic rats treated with diuretics plus oral prodrug of guanfacine, green line). Mean measurements ± SD of three rats studied at a time in each group are depicted.
Fig 2.
Transient natriuretic effects in G4 (cirrhotic rats treated with furosemide and potassium canrenoate, yellow line) and G5 (cirrhotic rats treated with diuretics plus clonidine, blue line) over CCl4 weeks 11–12.
Progressive natriuretic effects in G6 (cirrhotic rats treated with diuretics plus oral prodrug of guanfacine, green line). Further groups depicted: G1 (healthy controls, black line), G3 (untreated cirrhotic rats, red line). Mean measurements ± SD of three rats studied at a time in each group are depicted.
Fig 3.
Graphical depiction of adrenergic hypertone in cirrhotic rats, treated (G4) or not (G3) with diuretics.
Early (G5) and late (G6) blunting of adrenergic function in cirrhotic rats receiving, respectively, clonidine or guanfacine, along with diuretics.
Table 2.
Comparisons between means ± SD of FENa, kaliuresis, plasma Na, etc. taken on weeks 11–12 (Group GXA) vs. weeks 13–14 (Group GXB) or among different G1–G6 groups. In each group, worsening of clinical parameters underlined, improvements in bold print (weeks 13–14, Group GXB, vs. weeks 11–12, Group GXA).
Table 3.
Comparisons between means ± SD of PRA, plasma aldosterone, etc. taken on weeks 11–12 (Group GXA) vs. weeks 13–14 (Group GXB) or among different G1–G6 groups. In each group, worsening of clinical parameters underlined, improvements in bold print (weeks 13–14, Group GXB, vs. weeks 11–12, Group GXA).
Fig 4.
Marked increase in PRA (concurrent with development of diuretic-unresponsive ascites) over CCL4 weeks 13–14 in cirrhotic rats (G3, untreated, red line, and G4, receiving diuretics only, yellow line).
Blunting of renin secretion in G5 (cirrhotic rats treated with diuretics plus clonidine, blue line) and G6 (cirrhotic rats treated with diuretics plus oral prodrug of guanfacine, green line). Further group depicted: G1 (untreated controls, black line). Mean measurements ± SD of three rats studied at a time in each group are depicted.